Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study
- PMID: 40349730
- DOI: 10.1016/j.jinf.2025.106500
Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study
Abstract
Objectives: To describe the symptom burden and associated impairment two years after SARS-CoV-2 index infection.
Methods: Participants of an earlier large population-based survey in Southwestern Germany (August-September 2021) were contacted again in November 2023. We calculated the prevalences of suspected PCS and specific symptom clusters at both time points and investigated factors for their resolution or emergence.
Results: A total of 6635 subjects (mean age 46.6 years, 60.9% females) participated in the follow-up. Between baseline and follow-up (median 8.7 and 23.9 months after infection) there were only small changes in the point prevalence of post-COVID-19 syndrome (PCS) (29.9% versus 31.2%) or defined symptom clusters such as fatigue (23.8% versus 22.0%), neurocognitive impairment (15.8% versus 17.3%), or chest symptoms (14.4% versus 13.7%). Probabilities of resolution were often similar to probabilities of emergence, e.g. fatigue symptoms resolved in 9.8% of participants but emerged in 8.0%. Consistent predictors for emerging symptom clusters were female sex, obesity and medical treatment of the acute infection. The six main symptom clusters together explained 45% (physical domain) and 29% (mental domain) of the variance in health-related quality of life (hrQoL).
Conclusions: We found a remaining high symptom prevalence two years after SARS-CoV-2 infection, but symptoms present nine months after the index infection often resolved, which was associated with increasing hrQoL. Remarkably, a considerable portion of symptoms newly emerged, of which only a few could be attributed to reported SARS-CoV-2 reinfection.
Keywords: Health-related quality of life; Long COVID; Population-based cohort; Post-COVID-19 syndrome; Symptom persistence.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: A population-based, nested case-control study.PLoS Med. 2025 Jan 23;22(1):e1004511. doi: 10.1371/journal.pmed.1004511. eCollection 2025 Jan. PLoS Med. 2025. PMID: 39847575 Free PMC article.
-
Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.JAMA. 2022 Oct 25;328(16):1604-1615. doi: 10.1001/jama.2022.18931. JAMA. 2022. PMID: 36215063 Free PMC article.
-
Post-acute sequelae of covid-19 six to 12 months after infection: population based study.BMJ. 2022 Oct 13;379:e071050. doi: 10.1136/bmj-2022-071050. BMJ. 2022. PMID: 36229057 Free PMC article.
-
Post-coronavirus disease 2019-associated symptoms among children and adolescents in the SARS-CoV-2 Omicron era.Eur J Pediatr. 2024 Dec 21;184(1):96. doi: 10.1007/s00431-024-05919-3. Eur J Pediatr. 2024. PMID: 39707044 Free PMC article.
-
A pilot cross-sectional investigation of symptom clusters and associations with patient-reported outcomes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post COVID-19 Condition.Qual Life Res. 2024 Dec;33(12):3229-3243. doi: 10.1007/s11136-024-03794-x. Epub 2024 Oct 3. Qual Life Res. 2024. PMID: 39361124 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous